Novo Nordisk A/S’s (NVO) Overweight Rating Reiterated at Cantor Fitzgerald

Novo Nordisk A/S (NYSE:NVO)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a report issued on Thursday, Benzinga reports. They presently have a $160.00 target price on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 29.09% from the company’s previous close.

Several other analysts also recently issued reports on the stock. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective for the company. UBS Group initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating for the company. Finally, BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Trading Down 0.5 %

NVO stock traded down $0.59 on Thursday, hitting $123.94. 512,260 shares of the company were exchanged, compared to its average volume of 4,847,884. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $138.28. The business’s fifty day moving average is $126.28 and its two-hundred day moving average is $110.42. The stock has a market capitalization of $556.18 billion, a price-to-earnings ratio of 45.69, a price-to-earnings-growth ratio of 2.06 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. As a group, research analysts forecast that Novo Nordisk A/S will post 3.33 earnings per share for the current year.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of institutional investors have recently bought and sold shares of NVO. Cornerstone Planning Group LLC acquired a new stake in shares of Novo Nordisk A/S during the second quarter worth approximately $29,000. First PREMIER Bank acquired a new position in shares of Novo Nordisk A/S in the first quarter worth $25,000. Tower Research Capital LLC TRC boosted its position in Novo Nordisk A/S by 165.3% during the first quarter. Tower Research Capital LLC TRC now owns 199 shares of the company’s stock valued at $32,000 after purchasing an additional 124 shares during the last quarter. CNB Bank acquired a new position in Novo Nordisk A/S in the 4th quarter worth about $26,000. Finally, Pacific Center for Financial Services raised its stake in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.